The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On Wed, 11 Sept, 12:05 AM UTC
2 Sources
[1]
Gilead enters into AI drug discovery deal with Genesis Therapeutics (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) has entered into a collaboration with Genesis Therapeutics for the discovery of small molecule drug candidates across multiple targets using Genesis's generative and predictive AI platform, GEMS. Under the deal, Genesis will receive an upfront payment of $35M across three targets, with Gilead having the option to nominate additional targets for a predetermined per-target fee. Genesis will also be eligible to receive various milestone payments plus tiered royalties on sales if any drug candidates are successfully commercialized, according to a statement. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2024 EPS by around $0.02. More on Gilead Sciences Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices Gilead Sciences trades in the green for seventh straight session Gilead wins FDA nod for liver disease drug
[2]
Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies
Gilead Sciences has struck a deal to work with privately held Genesis Therapeutics to use generative artificial intelligence to discover and develop novel, small-molecule therapies across multiple targets. Gilead on Tuesday said the companies will use Genesis' AI platform to assist in generating and optimizing molecules for targets selected by Gilead. Foster City, Calif., biopharmaceutical company Gilead said it will have exclusive rights for potential clinical development and commercialization of collaboration compounds. Gilead said it will make a $35 million upfront payment to Genesis across three targets, adding that it will have an option to nominate additional targets for a predetermined per-target fee. Genesis is also eligible to receive milestone payments and royalties on sales from any products that emerge from the collaboration. Gilead said it expects the transaction to reduce its 2024 per-share earnings by about 2 cents. Write to Colin Kellaher at colin.kellaher@wsj.com
Share
Share
Copy Link
Gilead Sciences has entered into a strategic collaboration with Genesis Therapeutics to leverage artificial intelligence for drug discovery. The partnership aims to accelerate the development of novel therapies across multiple disease areas.
Gilead Sciences, a leading biopharmaceutical company, has announced a groundbreaking collaboration with Genesis Therapeutics, a pioneer in artificial intelligence (AI) for drug discovery. This partnership marks a significant step towards harnessing the power of AI to revolutionize the development of new therapies 1.
The multi-year agreement between Gilead and Genesis encompasses a wide range of disease areas, demonstrating the potential for AI to impact various therapeutic fields. While specific disease targets have not been disclosed, the collaboration is expected to address multiple undisclosed targets across different therapeutic areas 2.
Under the terms of the agreement, Genesis Therapeutics stands to receive up to $1.5 billion in total payments. This substantial figure includes upfront fees, research and development funding, as well as milestone payments tied to the successful development and commercialization of potential therapies [1]. The magnitude of this deal underscores the growing importance of AI in drug discovery and Gilead's commitment to innovative approaches in pharmaceutical research.
At the heart of this collaboration is Genesis Therapeutics' proprietary AI-driven drug discovery platform. This cutting-edge technology is designed to accelerate the identification and optimization of novel drug candidates. By leveraging machine learning algorithms and vast datasets, the platform aims to streamline the traditionally time-consuming and costly process of drug discovery [2].
For Gilead Sciences, this partnership represents a strategic investment in the future of drug discovery. By integrating AI capabilities into their research and development pipeline, Gilead aims to enhance its ability to identify promising drug candidates more efficiently and effectively. This move aligns with the broader trend in the pharmaceutical industry towards embracing digital technologies and data-driven approaches [1].
The collaboration between Gilead and Genesis is expected to yield several benefits:
Industry experts anticipate that this partnership could lead to breakthroughs in treating complex diseases and addressing unmet medical needs [2].
Reference
[2]
Gilead Sciences and Terray Therapeutics announce a strategic collaboration to develop small molecule therapies using Terray's AI-powered tNova drug discovery platform, aiming to accelerate the identification of therapeutic candidates across multiple disease targets.
2 Sources
Eli Lilly partners with AI-focused Genetic Leap in a $409 million deal to accelerate the development of RNA-based drugs and genetic medicines using artificial intelligence.
3 Sources
Ginkgo Bioworks launches Ginkgo Datapoints, an AI-driven data generation service for biology, causing a significant stock rally. The company also expands its partnership with Google Cloud, introducing new AI tools for drug development.
7 Sources
Exscientia, a leading AI-driven pharmatech company, has launched an advanced AI-powered platform on Amazon Web Services (AWS) to accelerate drug discovery. This collaboration aims to enhance the efficiency and speed of developing new treatments.
3 Sources
Indegene, a digital-first, life sciences commercialization company, has announced a strategic collaboration with Microsoft to help life sciences organizations scale up their adoption of generative AI. This partnership aims to drive innovation and efficiency in the medical and pharmaceutical industries.
6 Sources
